ALLIANCE A221805

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Colon, Gastrointestinal, Rectal

Status:

Closed

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Eligible for screening study DCP 001

A221805, Phase II, is closed to accrual effective March 31, 2023, at 4:30 ET.  If interim analysis is positive, Phase III will open to accrual.

A221805-Substudy SI1 is closed to accrual, effective September 15, 2022, at 4:30pm ET.

NCT#04137107